Nitroglycerin prevents coagulopathies and foetal death associated with abnormal maternal inflammation in rats

Summary

Inflammation-associated foetal loss is often linked to maternal coagulopathies. Here, we characterised the role of maternal inflammation in the development of various systemic maternal coagulopathies and foetal death during mid-to-late gestation in rats. Since nitric oxide (NO) functions as an inhibitor of platelet aggregation and antioxidant, we also tested whether the NO mimetic nitroglycerin (glyceryl trinitrate, GTN) prevents inflammation-associated coagulopathies and foetal death. To induce chronic inflammation, pregnant Wistar rats were injected with low-doses of lipopolysaccharide (LPS; 10–40 μg/kg) on gestational days (GD) 13.5–16.5. To determine whether the effects of inflammation are mediated by tumour necrosis factor-α (TNF-α), the TNF-α inhibitor etanercept was injected on GD 13.5 and 15.5. Controls consisted of rats injected with saline. GTN was administered to LPS-treated rats via daily application of a transdermal patch on GD 12.5–16.5. Using thromboelastography (TEG), various coagulation parameters were assessed on GD 17.5; foetal viability was determined morphologically. Reference coagulation parameters were established based on TEG results obtained from control animals. LPS-treated rats exhibited distinct systemic coagulopathies: hypercoagulability, hypocoagulability, hyperfibrinolysis, and disseminated intravascular coagulation (DIC) stages I and III. A specific foetal death coagulation phenotype was observed, implicating TEG as a potential tool to identify inflammation-induced haemostatic alterations associated with pregnancy loss. Treatment with etanercept reduced the incidence of coagulopathy by 47%, while continuous delivery of GTN prevented foetal death and the inflammation-induced coagulopathies. These findings provide a rationale for investigating the use of GTN in the prevention of maternal coagulopathies and inflammation-mediated foetal death.

Keywords

Thromboelastography - pregnancy - disseminated intravascular coagulation (DIC) - nitric oxide/NO - etanercept

• References

• 1 Silver RM. Fetal death. Obstet Gynecol 2007; 109: 153-167.
• 2 McNamee K, Dawood F, Farquharson RG. Thrombophilia and early pregnancy loss. Best Pract Res Clin Obstet Gynaecol. 2011 epub ahead of print.
• 3 Definitions of infertility and recurrent pregnancy loss. Fertil Steril. 2008 90. S60.
• 4 Brenner B. Hypercoagulability and recurrent miscarriages. Clin Adv Hematol Oncol 2010; 08: 467-469.
• 5 Kwak-Kim J, Park JC, Ahn HK. et al. Immunological modes of pregnancy loss. Am J Reprod Immunol 2010; 63: 611-623.
• 6 Challis JR, Lockwood CJ, Myatt L. et al. Inflammation and pregnancy. Reprod Sci 2009; 16: 206-215.
• 7 Stirling Y, Woolf L, North WR. et al. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52: 176-182.
• 8 Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003; 16: 153-168.
• 9 Rey E, Kahn SR, David M. et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361: 901-908.
• 10 Kovalevsky G, Gracia CR, Berlin JA. et al. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. Arch Intern Med 2004; 164: 558-563.
• 11 Brenner B, Sarig G, Weiner Z. et al. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost 1999; 82: 6-9.
• 12 Robertson L, Wu O, Langhorne P. et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132: 171-196.
• 13 Werner EF, Lockwood CJ. Thrombophilias and stillbirth. Clin Obstet Gynecol 2010; 53: 617-627.
• 14 Bonnar J, McNicol GP, Douglas AS. Coagulation and fibrinolytic systems in preeclampsia and eclampsia. Br Med J 1971; 02: 12-16.
• 15 Renaud SJ, Cotechini T, Quirt JS. et al. Spontaneous pregnancy loss mediated by abnormal maternal inflammation in rats is linked to deficient uteroplacental perfusion. J Immunol 2011; 186: 1799-1808.
• 16 Isermann B, Sood R, Pawlinski R. et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med 2003; 09: 331-337.
• 17 Woodhams BJ, Candotti G, Shaw R. et al. Changes in coagulation and fibrinolysis during pregnancy: evidence of activation of coagulation preceding spontaneous abortion. Thromb Res 1989; 55: 99-107.
• 18 Li M, Huang SJ. Innate immunity, coagulation and placenta-related adverse pregnancy outcomes. Thromb Res 2009; 124: 656-662.
• 19 Sarig G, Brenner B. Coagulation, inflammation, and pregnancy complications. Lancet 2004; 363: 96-97.
• 20 Peitsch MC, Jongeneel CV. A 3-D model for the CD40 ligand predicts that it is a compact trimer similar to the tumor necrosis factors. Int Immunol 1993; 05: 233-238.
• 21 Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131: 417-430.
• 22 Berman J, Girardi G, Salmon JE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005; 174: 485-490.
• 23 Silver RM, Lohner WS, Daynes RA. et al. Lipopolysaccharide-induced fetal death: the role of tumor-necrosis factor alpha. Biol Reprod 1994; 50: 1108-1112.
• 24 Makhseed M, Raghupathy R, Azizieh F. et al. Circulating cytokines and CD30 in normal human pregnancy and recurrent spontaneous abortions. Hum Reprod 2000; 15: 2011-2017.
• 25 Raghupathy R. Th1-type immunity is incompatible with successful pregnancy. Immunol Today 1997; 18: 478-482.
• 26 Ng SC, Gilman-Sachs A, Thaker P. et al. Expression of intracellular Th1 and Th2 cytokines in women with recurrent spontaneous abortion, implantation failures after IVF/ET or normal pregnancy. Am J Reprod Immunol 2002; 48: 77-86.
• 27 Redecha P, Tilley R, Tencati M. et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007; 110: 2423-2431.
• 28 Falcón BJ, Cotechini T, Othman M. et al. Abnormal inflammation leads to maternal coagulopathies associated with placental haemostatic alterations in a rat model of foetal loss. Thromb Haemost 2012; 107: 438-447.
• 29 Gris JC, Mercier E, Quere I. et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103: 3695-3699.
• 30 Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibodyinduced fetal loss by inhibiting complement activation. Nat Med 2004; 10: 1222-1226.
• 31 Lam JY, Chesebro JH, Fuster V. Platelets, vasoconstriction, and nitroglycerin during arterial wall injury. A new antithrombotic role for an old drug. Circulation 1988; 78: 712-716.
• 32 Kayanoki Y, Kawata S, Yamasaki E. et al. Reduced nitric oxide production by L-arginine deficiency in lysinuric protein intolerance exacerbates intravascular coagulation. Metabolism 1999; 48: 1136-1140.
• 33 Hummel SG, Fischer AJ, Martin SM. et al. Nitric oxide as a cellular antioxidant: a little goes a long way. Free Radic Biol Med 2006; 40: 501-506.
• 34 Lowe DT. Nitric oxide dysfunction in the pathophysiology of preeclampsia. Nitric Oxide 2000; 04: 441-458.
• 35 Tempfer C, Unfried G, Zeillinger R. et al. Endothelial nitric oxide synthase gene polymorphism in women with idiopathic recurrent miscarriage. Hum Reprod 2001; 16: 1644-1647.
• 36 Paradisi R, Fabbri R, Battaglia C. et al. Nitric oxide levels in women with missed and threatened abortion: results of a pilot study. Fertil Steril 2007; 88: 744-748.
• 37 Kol A, Borjesson DL. Application of thrombelastography/thromboelastometry to veterinary medicine. Vet Clin Pathol 2010; 39: 405-416.
• 38 Wiinberg B, Kristensen AT. Thromboelastography in veterinary medicine. Semin Thromb Hemost 2010; 36: 747-756.
• 39 Othman M, Powell S, Chirinian Y. et al. Thromboelastography reflects global hemostatic variation among severe haemophilia A dogs at rest and following acute exercise. Haemophilia 2009; 15: 1126-1134.
• 40 Moreland LW, Schiff MH, Baumgartner SW. et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478-486.
• 41 Othman M, Falcon BJ, Kadir R. Global hemostasis in pregnancy: are we using thromboelastography to its full potential?. Semin Thromb Hemost 2010; 36: 738-746.
• 42 Orlikowski CE, Rocke DA, Murray WB. et al. Thrombelastography changes in pre-eclampsia and eclampsia. Br J Anaesth 1996; 77: 157-161.
• 43 Schafer AI. The hypercoagulable states. Ann Intern Med 1985; 102: 814-828.
• 44 Fust G, Bertok L, Juhasz-Nagy S. Interactions of radio-detoxified Escherichia coliendotoxin preparations with the complement system. Infect Immun 1977; 16: 26-31.
• 45 Bick RL. Coagulation abnormalities in malignancy: a review. Semin Thromb He-most 1992; 18: 353-372.
• 46 Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008; 08: 776-787.
• 47 Thachil J, Toh CH. Disseminated intravascular coagulation in obstetric disorders and its acute haematological management. Blood Rev 2009; 23: 167-176.
• 48 Maslow AD, Breen TW, Sarna MC. et al. Prevalence of coagulation abnormalities associated with intrauterine fetal death. Can J Anaesth 1996; 43: 1237-1243.
• 49 Hinshaw LB, Tekamp-Olson P, Chang AC. et al. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock 1990; 30: 279-292.
• 50 Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988; 08: 5588-5592.
• 51 Reverdiau P, Jarousseau AC, Thibault G. et al. Tissue factor activity of syncytiotrophoblast plasma membranes and tumoral trophoblast cells in culture. Thromb Haemost 1995; 73: 49-54.
• 52 Rai R, Tuddenham E, Backos M. et al. Thromboelastography, whole-blood haemostasis and recurrent miscarriage. Hum Reprod 2003; 18: 2540-2543.
• 53 Iwaki T, Castellino FJ. Maternal fibrinogen is necessary for embryonic development. Curr Drug Targets 2005; 06: 535-539.
• 54 Leunen K, Hall DR, Odendaal HJ. et al. The profile and complications of women with placental abruption and intrauterine death. J Trop Pediatr 2003; 49: 231-234.
• 55 Kor-anantakul O, Lekhakula A. Overt disseminated intravascular coagulation in obstetric patients. J Med Assoc Thai 2007; 90: 857-864.
• 56 Ali J, Yeo A, Gana TJ. et al. Predictors of fetal mortality in pregnant trauma patients. J Trauma 1997; 42: 782-785.
• 57 Winger EE, Reed JL. Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol 2008; 60: 8-16.
• 58 Asagiri K, Nakatsuka M, Konishi H. et al. Involvement of peroxynitrite in LPS-induced apoptosis of trophoblasts. J Obstet Gynaecol Res 2003; 29: 49-55.
• 59 Guo Y, Longo CJ, Xie R. et al. Cost-effectiveness of transdermal nitroglycerin use for preterm labor. Value Health 2011; 14: 240-246.
• 60 Mitchell JA, Warner TD. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal antiinflammatory drugs. Nat Rev Drug Discov 2006; 05: 75-86.
• 61 Wang GR, Zhu Y, Halushka PV. et al. Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase. Proc Natl Acad Sci USA 1998; 95: 4888-4893.
• 62 Picunio S, Simioni M, Doni MG. Platelet activation and modulation of the induction of nitric oxide synthase in the conscious rat. Life Sci 1999; 65: 1463-1475.
• 63 Clowse ME, Magder LS, Witter F. et al. Early risk factors for pregnancy loss in lupus. Obstet Gynecol 2006; 107: 293-299.
• 64 Othman M, Labelle A, Mazzetti I. et al. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood 2007; 109: 2832-2839.
• 65 Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003; 04: 399-415.